A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03758339
- Locations
- ๐บ๐ธ
Covance Clinical Research Unit, Madison, Wisconsin, United States
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
- Conditions
- Advanced Ovarian CarcinomaAdvanced Breast Carcinoma
- Interventions
- Biological: ONT-10, Varlilumab combination
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02270372
- Locations
- ๐บ๐ธ
NYU Perlmutter Cancer Center, New York, New York, United States
๐บ๐ธUAB Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธUniversity of Colorado, Aurora, Colorado, United States
Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Biological: ONT-10
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01978964
- Locations
- ๐บ๐ธ
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01616199
- Locations
- ๐บ๐ธ
New York University, New York, New York, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
Phase 1 Study of ONT-10 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- Biological: ONT-10
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01556789
- Locations
- ๐บ๐ธ
University of Colorado Cancer Center, Aurora, Colorado, United States
๐บ๐ธMary Crowley Cancer Research Center, Dallas, Texas, United States
๐บ๐ธNorthwest Medical Specialties, PLLC, Tacoma, Washington, United States
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01408316
- Locations
- ๐บ๐ธ
Comprehensive Clinical Development NW, Tacoma, Washington, United States
Phase 1 and 2 Study of PX-866 and Cetuximab
- Conditions
- Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckIncurable Metastatic Colorectal Carcinoma
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT01252628
- Locations
- ๐บ๐ธ
Southwest Cancer Care, Escondido, California, United States
๐บ๐ธMonterey Bay Oncology, Monterey, California, United States
๐จ๐ฆMaisonneuve-Rosemont Hospital Research Centre, Montreal, Quebec, Canada
Study of PX-866 and Docetaxel in Solid Tumors
- Conditions
- Non Small Cell Lung Cancer (NSCLC)Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT01204099
- Locations
- ๐บ๐ธ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐จ๐ฆCHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
๐บ๐ธUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00736372
- Locations
- ๐บ๐ธ
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
๐บ๐ธTyler Cancer Center, Tyler, Texas, United States
๐บ๐ธTGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, Arizona, United States
Phase I Trial of Oral PX-866
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT00726583
- Locations
- ๐บ๐ธ
M.D. Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Colorado Health Sciences Center, Aurora, Colorado, United States